NRIX — what changed in the latest 10-Q

Text added vs the prior filing · source: 10-Q · 2026-10-13

• Our targeted protein degradation portfolio includes bexobrutideg (NX‑5948), an investigational, orally bioavailable, highly selective degrader of the B‑cell signaling protein BTK for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. We are developing be…

• Zelebrudomide (NX-2127): We previously were developing zelebrudomide (NX‑2127), an investigational orally bioavailable degrader that simultaneously degrades BTK and the cereblon neosubstrates IKZF1 (Ikaros) and IKZF3 (Aiolos), in a Phase 1 clinical trial in patients with relapsed or refractory B-cel…

• We have entered into several revenue-generating collaborations with large biopharmaceutical companies, including collaborations with Gilead, Sanofi and Pfizer to leverage our DEL-AI platform for drug discovery, and a collaboration with Roche to develop and commercialize bexobrutideg. In aggregate, a…

• In June 2026, we entered into a strategic collaboration with F. Hoffmann-La Roche Ltd. and Genentech, Inc. (together, Roche), to develop, manufacture, commercialize and otherwise exploit bexobrutideg (NX-5948) (the Roche Collaboration Agreement). The Roche Collaboration Agreement became effective in…

• Under the Roche Collaboration Agreement, we granted Roche an exclusive, worldwide license, including with respect to us and our affiliates, to develop, manufacture, commercialize and otherwise exploit bexobrutideg and products containing bexobrutideg (the Development and Commercialization License). …

Text removed vs the prior filing · source: 10-Q · 2026-07-09

• Our portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948), an investigational, orally bioavailable, highly selective BTK degrader for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases, and zelebrudom…

• Zelebrudomide (NX‑2127): We are currently conducting a Phase 1a/1b dose-escalation and cohort expansion study of zelebrudomide in patients with relapsed or refractory B-cell malignancies. We previously initiated Phase 1b expansion cohorts for patients with relapsed CLL, diffuse large B-cell lymphoma…

• We have entered into several revenue generating collaborations with large biopharmaceutical companies, including Gilead, Sanofi and Pfizer, to leverage our DEL-AI platform for drug discovery. In aggregate, as of May 31, 2026, we had received $489.0 million in non-dilutive financing from these collab…

• On June 6, 2026, we entered into the Roche Collaboration Agreement to develop, manufacture, commercialize and otherwise exploit bexobrutideg (NX-5948). Under the terms of the Roche Collaboration Agreement, we will receive an upfront cash payment of $700.0 million and are eligible to receive developm…

• Since the commencement of our operations, we have devoted substantially all of our resources to conducting research and development activities, establishing and maintaining our intellectual property portfolio, establishing our corporate infrastructure, raising capital and providing general and admin…

Text added vs the prior filing · source: 10-Q · 2026-10-13

• We currently have evolving safety data for bexobrutideg and limited safety data for our other drug candidates in humans. Although some of our drug candidates have produced observable safety findings in animal studies, these findings may not translate to the clinical setting. Similarly, the chemical …

• Serious adverse events, undesirable side effects or unexpected characteristics could arise at any time during preclinical or clinical development of our drug candidates. Many drug candidates that showed promise in early-stage testing for treating cancer or other diseases later have been found to cau…

• To date, relatively few clinical trials have studied small molecule drug candidates designed to control cellular protein levels through targeted protein degradation, and clinical experience with small molecule CBL-B inhibitors remains limited. We have not completed clinical trials for any of our dru…

• As our Phase 3 clinical trial for bexobrutideg generates additional safety data across a larger and potentially more varied patient population, it may reveal safety or tolerability concerns, adverse effects in particular subgroups, effects associated with unintended degradation of non-target protein…

• As future clinical trials of NX-1607 generate additional safety data across larger or more varied patient populations, they may reveal adverse events that were not observed in earlier studies. Because NX-1607 inhibits CBL-B, a negative regulator of T-cell activation, these adverse events could inclu…

Text removed vs the prior filing · source: 10-Q · 2026-07-09

• In addition, we filed for and received an Innovation Passport designation for NX-1607 in the United Kingdom (UK) in February 2022. The Innovation Passport is the mandated entry point to the Innovative Licensing and Access Pathway (ILAP) in the UK to facilitate approval of and market access to an inn…

• We are in the early stages of clinical development of bexobrutideg and zelebrudomide and we currently have limited safety data of bexobrutideg and zelebrudomide in humans. Although some of our drug candidates have produced observable results in animal studies, these drug candidates may not demonstra…

• We have recently begun to evaluate our lead drug candidates in human clinical trials, and there have been very few clinical trials to date involving small molecule drug candidates designed to control cellular protein levels through targeted protein degradation. It is impossible to predict when or if…

• A potential risk in any protein degradation product is that healthy proteins or proteins not targeted for degradation will be degraded or that the degradation of the targeted protein in itself could cause adverse events, undesirable side effects or unexpected characteristics. It is possible that hea…

• If any drug candidates we develop are associated with serious adverse events or undesirable side effects, or have characteristics that are unexpected, including in preclinical studies, we may need to abandon their development or limit development to certain uses or subpopulations in which the advers…